S&P MERVAL Index Ends 3.78% Lower at 1197524.35 — Data Talk
The S&P MERVAL Index is down 46999.40 points or 3.78% today to 1197524.35
--Largest one-day point decline since Tuesday, March 5, 2024
--Largest one-day percentage decline since Monday, March 11, 2024
--Down for two consecutive trading days
--Down 61779.03 points or 4.91% over the last two trading days
--Largest two-day point and percentage decline since Tuesday, March 5, 2024
--Down three of the past four trading days
--Off 9.02% from its record close of 1316204.45 hit Friday, Feb. 2, 2024
--Lowest closing value since Thursday, April 4, 2024
--Off 9.02% from its 52-week high of 1316204.45 hit Friday, Feb. 2, 2024
--Up 334.82% from its 52-week low of 275405.88 hit Wednesday, April 19, 2023
--Rose 325.72% from 52 weeks ago
--Off 9.02% from its 2024 closing high of 1316204.45 hit Friday, Feb 2, 2024
--Up 28.71% from its 2024 closing low of 930419.67 hit Tuesday, Jan. 2, 2024
--Month-to-date it is down 1.32%
--Year-to-date it is up 267820.16 points or 28.81%
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 15, 2024 17:25 ET (21:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year